Tumor necrosis factor antagonists and their use in endometriosis
AssigneeApplied Research Systems ARS Holding N.V.
InventorsFrancesco Borrelli, Mauro D'Antonio, Fabrizio Martelli
Life of this patent
Estimating the term…
Abstract
Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected from among several classes but preferably are soluble TNF receptors. The antagonists are useful for the regression of endometriotic lesions and, if combined with other active ingredients, for amelioration of related disorders, like infertility.
Claims6
A method for treating endometriosis, comprising administering to a patient in need thereof a therapeutically effective amount of sequestering antagonist.
A method for improving implantation and fertility rate by reducing endometriotic lesions, comprising administering to a patient in need thereof a therapeutically effective amount of a TNF sequestering antagonist.
Dependencies are inferred from the claim text.